AGIOS PHARMACEUTICALS, INC. Stockholders Equity

Quick Answer

AGIOS PHARMACEUTICALS, INC. reported Stockholders Equity of $1.19 billion for fiscal year 2025.

AGIOS PHARMACEUTICALS, INC. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $1.19B -22.6%
2024 $1.54B +90.0%
2023 $811.02M -26.3%
2022 $1.10B -14.8%
2021 $1.29B +223.4%
2020 $399.50M -37.6%
2019 $640.53M -6.8%
2018 $687.54M +83.1%
2017 $375.50M +4.7%
2016 $358.59M +3.9%
2015 $345.12M -18.7%
2014 $424.37M +222.8%
2013 $131.48M +282.6%
2012 -$72.02M -36.5%
2011 -$52.78M -78.4%
2010 -$29.59M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $1.28B -21.0% -6.2%
June 30, 2025 $1.37B +107.3% -6.6%
March 31, 2025 $1.47B +97.1% -4.8%
December 31, 2024 $1.54B +90.0% -5.3%
September 30, 2024 $1.63B +83.4% +146.3%
June 30, 2024 $660.51M -31.5% -11.2%
March 31, 2024 $743.92M -28.2% -8.3%
December 31, 2023 $811.02M -26.3% -8.5%
  • AGIOS PHARMACEUTICALS, INC. showed a decrease of -22.6% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2010–2025 period, AGIOS PHARMACEUTICALS, INC.’s stockholders equity has grown by 4132.0% (from -$29.59 million to $1.19 billion).
  • The most recent figure is from AGIOS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment